In a filing, CRISPR Therapeutics AG revealed its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $0.41 million on Mar 21 ’25. In the deal valued at $41.23 per share,10,031 shares were sold. As a result of this transaction, Kulkarni Samarth now holds 195,085 shares worth roughly $6.64 million.
Then, Bruno Julianne sold 1,714 shares, generating $70,668 in total proceeds. Upon selling the shares at $41.23, the Chief Operating Officer now owns 10,544 shares.
Before that, Prasad Raju sold 2,197 shares. CRISPR Therapeutics AG shares valued at $90,582 were divested by the Chief Financial Officer at a price of $41.23 per share. As a result of the transaction, Prasad Raju now holds 16,767 shares, worth roughly $0.57 million.
Evercore ISI upgraded its CRISPR Therapeutics AG [CRSP] rating to an Outperform from a an In-line in a research note published on February 14, 2025; the price target was increased to $99 from $60. A number of analysts have revised their coverage, including TD Cowen’s analysts, who increased its forecast for the stock in mid February from “a Sell” to “a Hold”. H.C. Wainwright began covering CRSP with “Buy” recommendation on February 03, 2025. Needham maintained its rating on August 06, 2024. It rated CRSP as “a Buy”.
Price Performance Review of CRSP
On Monday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock fall -8.00% to $34.03. Over the last five days, the stock has lost -20.15%. CRISPR Therapeutics AG shares have fallen nearly -13.54% since the year began. Nevertheless, the stocks have fallen -51.50% over the past one year. While a 52-week high of $68.39 was reached on 02/19/25, a 52-week low of $36.52 was recorded on 03/31/25. SMA at 50 days reached $42.78, while 200 days put it at $47.62.
Levels Of Support And Resistance For CRSP Stock
The 24-hour chart illustrates a support level at 32.74, which if violated will result in even more drops to 31.46. On the upside, there is a resistance level at 35.53. A further resistance level may holdings at 37.04. The Relative Strength Index (RSI) on the 14-day chart is 28.87, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.18, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.64%. Stochastics %K at 4.16% indicates the stock is a buying.
How much short interest is there in CRISPR Therapeutics AG?
A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on 2025-03-14, dropping by 99631.0 shares to a total of 20.31 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 20.41 million shares. There was a decline of -0.49%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 02, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $90 price target.
